Unimed Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Seoul Korea, Democratic People's Republic of (1990)
Status: Acquired by Solvay (1999) → now Abbott (2009)

Organization Overview

First Clinical Trial
1995
NCT00002444
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Unimed Laboratories CJSC | UNIMED Medical Institute | ZAO Unimed Laboratories

Active Ingredients

Marketed Drugs (1)

dronabinol (marinol) (NDA)

Drugs in Phase 3 Trials (2)

Goflikicept (5 trials)

placental tissue extract (1 trial)

Drugs in Phase 2 Trials (3)

celecoxib (celebrex) (1 trial)

diclofenac (voltaren) (1 trial)

testosterone (delatestryl) (2 trials)

Drugs in Phase 1 Trials (3)

alpha-lipoic acid (1 trial)

nitazoxanide (Alinia) (1 trial)

pregabalin (lyrica) (1 trial)

Indications

Approved Indications


 

Anorexia

Chronic Pain

Nausea

Vomiting

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis, Gouty (Phase 2)

Breast Neoplasms (Phase 2)

Gout (Phase 2)

HIV Infections (Phase 1)

Hypogonadism (Phase 2)

Pericarditis (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 8